BLRX - BioLineRx GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
- M.S.Q. Ventures on Wednesday said its client BioLineRx ( NASDAQ: BLRX ) had entered into an agreement with China-based GenFleet Therapeutics for the co-development of inhibitor Motixafortide to treat a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC).
- As per the deal, GenFleet will design and run a randomized phase 2b clinical trial that will enroll about 200 first-line metastatic PDAC patients in China.
- The trial will evaluate the superiority of Motixafortide in combination with anti-PD-1 and chemotherapy vs. chemotherapy alone.
- U.S.-listed shares of BLRX were down 3.9% at $1.25 in premarket trading.
For further details see:
BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer